2022-03-31 08:25:28 PRTG Portage Biotech
03/31/22 03/3108:25 03/31/2208:25 | Portage Biotech provides update on clinical-stage, development programsPortage Biotech provided an update on its clinical development programs and announced its development goals for the remainder of 2022. Q2-Q4 2022 Development Focus: The Company remains focused on advancing its pipeline of novel immuno-oncology therapeutics designed to prevent and overcome cancer treatment resistance. Clinical trials were initiated in 2021 for both of Portage's lead invariant natural killer T cell, iNKT, agonist programs, PORT-2 and PORT-3. Preliminary Phase 1 data received to date suggests PORT-2 was well tolerated when administered as a monotherapy, with no related adverse events. This has enabled a plan to accelerate opening of the combination safety cohort with Keytruda, in parallel with the ongoing high dose monotherapy cohort. Portage has decided to expand the PORT-2 study beyond the UK to accelerate clinical studies while addressing COVID-19 headwinds. The Company has hired a global clinical research organization and is preparing for regulatory submissions in other countries. Preliminary safety data for repeat dosing of PORT-3, a nanoparticle co-formulation of PORT-2 and NY-ESO-1 immunogenic peptides developed for the treatment of NY-ESO-1 positive solid tumors, is also favorable. The Company expects to submit data to a scientific congress for PORT-3 later this year. New Collaborations with Academic Partners to Enhance Strategic Goals: As part of its broader research and development strategy, Portage is partnering with experts and companies that could bring additional expertise and insights to help advance the science and open new avenues for development. New collaborations include a partnership with Dr. Francis Mussai and Dr. Carmela De Santo at University of Birmingham on iNKTs. Portage is also initiating a second collaboration with Dr. Robert Negrin and his team at Stanford University to evaluate the use of PORT-2 with iNKT cell therapies in animals. Clinical Development Goals for the Remainder of 2022: Generate safety and efficacy data on all products currently in clinical trials - PORT-2: iNKT agonist to treat melanoma and non-small cell lung cancer; initial efficacy data anticipated by the end of 2022. PORT-3: iNKT agonist co formulated in a nanoparticle with NY-ESO-1 peptide vaccine in tumors that express NY-ESO-1; preliminary efficacy data in patients expected year end, going into 2023. PORT-1: intratumoral amphiphilic formulation, developed in collaboration with our affiliate Intensity, being evaluated as a monotherapy and in combination with Keytruda and Yervoy to treat multiple solid tumors; multiple readouts expected in 2H 2022. Prepare additional compounds to enter clinical studies - PORT-5: Systemically delivered STING agent developed in collaboration with our affiliate Stimunity, is progressing towards the clinic. Continue to explore collaboration opportunities for all of our assets and evaluate new opportunities to expand immuno-oncology product portfolio |
|
---|
Hot Stocks
|
Deutsche Bank raises prime lending rate to 7.75% »
18:25 02/01/23 02/0118:25 02/01/2318:25
DB
Deutsche Bank
Deutsche Bank announced… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Spotify price target raised to $132 from $115 at Truist »
18:24 02/01/23 02/0118:24 02/01/2318:24
SPOT
Spotify
Truist analyst Matthew… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Thermo Fisher CEO: Very excited about potential growth in China in 2023 »
18:22 02/01/23 02/0118:22 02/01/2318:22
TMO
Thermo Fisher
He said China is the… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Qualtrics downgraded to Hold from Buy at Deutsche Bank »
18:18 02/01/23 02/0118:18 02/01/2318:18
XM
Qualtrics
Deutsche Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Peloton downgraded to Market Perform from Outperform at JMP Securities »
18:15 02/01/23 02/0118:15 02/01/2318:15
PTON
Peloton
JMP Securities analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Northern Trust raises prime rate to 7.75% from 7.50% »
18:11 02/01/23 02/0118:11 02/01/2318:11
NTRS
Northern Trust
Northern Trust has… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
SK Hynix upgraded to Conviction Buy from Buy at Goldman Sachs »
18:04 02/01/23 02/0118:04 02/01/2318:04
HXSCL
SK Hynix
Goldman Sachs analyst… Story temporarily locked. |
Hot Stocks
|
OSI Systems CEO sells $1.86M in common stock »
17:59 02/01/23 02/0117:59 02/01/2317:59
OSIS
OSI Systems
In a regulatory filing,… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Arcos Dorados reports Q4 SSS up 35.7% with revenue over $1B for the quarter »
17:44 02/01/23 02/0117:44 02/01/2317:44
ARCO
Arcos Dorados
Adjusted EBITDA in the… Story temporarily locked. ShowHide Related Items >><<
|
General news
|
Fed policy outlook: the FOMC hiked rates another 25 bps »
17:40 02/01/23 02/0117:40 02/01/2317:40
$ECON
Economic Data
Fed policy outlook: the… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Match Group downgraded to Perform from Outperform at Oppenheimer »
17:39 02/01/23 02/0117:39 02/01/2317:39
MTCH
Match Group
Oppenheimer analyst Jason… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Webster Financial raises prime lending rate to 7.75% from 7.5%, effective Feb 2
17:37 02/01/23 02/0117:37 02/01/2317:37
WBS
Webster Financial
ShowHide Related Items >><<
|
Hot Stocks
|
Dollar General enters agreement for $750M, 364-day revolving credit facility »
17:36 02/01/23 02/0117:36 02/01/2317:36
DG
Dollar General
On January 31, Dollar… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Texas Instruments to hold a conference call »
17:35 02/01/23 02/0117:35 02/01/2317:35
TXN
Texas Instruments
SVP & CFO Lizardi and… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Brandywine Realty sees FY23 FFO $1.12-$1.20, consensus $1.19
17:33 02/01/23 02/0117:33 02/01/2317:33
BDN
Brandywine Realty
ShowHide Related Items >><<
|
Earnings
|
Brandywine Realty reports Q4 FFO 32c, consensus 32c »
17:32 02/01/23 02/0117:32 02/01/2317:32
BDN
Brandywine Realty
Reports Q4 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Citizens Bank raises prime lending rate to 7.75% from 7.5% »
17:32 02/01/23 02/0117:32 02/01/2317:32
CFG
Citizens Financial
Citizens Financial… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
U.S. Bank raises prime lending rate to 7.75% from 7.5% »
17:31 02/01/23 02/0117:31 02/01/2317:31
USB
U.S. Bancorp
U.S. Bancorp announced it… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Arcos Dorados to host conference call »
17:30 02/01/23 02/0117:30 02/01/2317:30
ARCO
Arcos Dorados
Investor update… Story temporarily locked. ShowHide Related Items >><<
|
General news
| Treasury Market Summary:… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
TC Energy upgraded to Outperformer from Neutral at CIBC »
17:29 02/01/23 02/0117:29 02/01/2317:29
TRP
TC Energy
CIBC analyst Robert… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
OncoSec files to sell 6.19M shares of common stock
17:26 02/01/23 02/0117:26 02/01/2317:26
ONCS
OncoSec
ShowHide Related Items >><<
|
Hot Stocks
|
TrueBlue sees FY23 CapEx $36M-$40M »
17:25 02/01/23 02/0117:25 02/01/2317:25
TBI
TrueBlue
Sees FY23 gross margin… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
TeraWulf files to sell common stock, no amount given »
17:25 02/01/23 02/0117:25 02/01/2317:25
WULF
TeraWulf
JonesTrading… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B »
17:25 02/01/23 02/0117:25 02/01/2317:25
META
Meta Platforms
Cuts FY23 CapEx view to… Story temporarily locked. ShowHide Related Items >><<
|